Skip to main content
Caplight Logo









Derm-Biome Pharmaceuticals

Derm-Biome Pharmaceuticals

Private
VancouverHealthcare & Life Scienceshttps://www.crossroadsracingseries.com/

Last Round

Grant

May 8, 2024

Total Funding Raised

$328,000

Company Overview

Derm-Biome Pharmaceuticals is a biotechnology company that develops novel topical therapies for inflammatory skin diseases, precancerous skin conditions, and aging skin.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverytopical therapiespreclinical researchdermatologybiotech startupinflammatory skin diseaseoncologysmall-molecule drugsactinic keratosis treatmentatopic dermatitisdrug pipelinebiopharmapreclinical pharmacologytherapeutic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Derm-Biome Pharmaceuticals Comparables

Compare Derm-Biome Pharmaceuticals with similar companies based on industry and business-model similarity.

Derm-Biome Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
DFB Pharmaceuticals
79%
Vertes Therapeutics
79%
Vidac Pharma Holding PLC
78%

Derm-Biome Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 8, 2024
SeedApr 17, 2024
Pre SeedJul 2, 2020

Derm-Biome Pharmaceuticals Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 8, 2024

    $328K grant received from Canadian government agencies.

Derm-Biome Pharmaceuticals Filings

Explore SEC and related filing metadata, where available.

Derm-Biome Pharmaceuticals filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Derm-Biome Pharmaceuticals's valuation, stock price, and market status.

Is Derm-Biome Pharmaceuticals a public or private company?

Derm-Biome Pharmaceuticals is a private company.

What is the current stock price of Derm-Biome Pharmaceuticals?

Derm-Biome Pharmaceuticals is a private company with no public stock price. No recent secondary market data is available.

How much is Derm-Biome Pharmaceuticals worth (valuation)?

Valuation information for Derm-Biome Pharmaceuticals is not publicly available.

Can I buy Derm-Biome Pharmaceuticals stock?

Derm-Biome Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Derm-Biome Pharmaceuticals's last funding round?

Derm-Biome Pharmaceuticals's most recent funding round was Grant on May 8, 2024.

Who are the main investors in Derm-Biome Pharmaceuticals?

Key investors in Derm-Biome Pharmaceuticals include Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada.

Will Derm-Biome Pharmaceuticals IPO soon?

No public IPO plans have been announced for Derm-Biome Pharmaceuticals.

How can I track Derm-Biome Pharmaceuticals secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Derm-Biome Pharmaceuticals's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersVancouver
Year FoundedN/A
Last FundingMay 8, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?